SK Bioscience holds pediatric infectious disease prevention symposium

SK Bioscience held an academic event for pediatricians nationwide to share the latest clinical insights on preventing infectious diseases in infants and young children.

The company said it hosted the "2026 New Vision Symposium" over two days starting Saturday at the Westin Seoul Parnas hotel in Gangnam-gu, Seoul.

The event focused on the latest clinical evidence and practical applications for major pediatric infectious diseases, including respiratory syncytial virus (RSV) in infants, meningococcal disease and pertussis.

On the first day, Korea University Ansan Hospital Professor Kim Yun-kyung chaired the session, with Bundang Seoul National University Hospital Professor Lee Hyun-ju and Korea University Guro Hospital Professor Yoon Yun-sun presenting updated guidelines for infant RSV prevention ahead of the upcoming season. Clinical experience with Beyfortus — an antibody drug for newborns and infants co-marketed with Sanofi Korea — and data on its efficacy in preventing lower respiratory tract disease were also shared.

On the second day, Im Hyun-taek, president of the Korean Pediatric Society, chaired a session on meningococcal and pertussis prevention. Seoul Metropolitan Government Boramae Medical Center Professor Han Mi-sun and Gangnam Severance Hospital Professor Choi Jun-sik reviewed age-specific vaccination strategies, with a focus on the clinical utility of Menquadfi — a quadrivalent meningococcal protein conjugate vaccine introduced in South Korea this year and approved for use from six weeks to 55 years of age.

The symposium aimed to share the latest clinical evidence on major infectious diseases in infants and young children with frontline medical staff, establish an early prevention-centered care paradigm for seasonal respiratory illnesses and invasive infections, and strengthen field-oriented academic collaboration.

"This was a meaningful occasion to share clinical experience and reflect on the value of vaccination across different life stages," said Yoo Su-an, head of SK Bioscience's domestic marketing division. "We will continue academic exchanges with medical professionals to help build a vaccination environment grounded in scientific evidence."